Theravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 13,314 Shares

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the sale, the senior vice president owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. This trade represents a 5.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH traded up $0.02 during mid-day trading on Wednesday, reaching $16.71. 386,153 shares of the company traded hands, compared to its average volume of 348,652. The company’s fifty day moving average is $16.49 and its two-hundred day moving average is $17.40. Theravance Biopharma, Inc. has a fifty-two week low of $10.44 and a fifty-two week high of $21.03. The stock has a market cap of $861.40 million, a PE ratio of 7.60 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The company had revenue of $17.70 million during the quarter. Research analysts forecast that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. TD Cowen raised their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, March 23rd. B. Riley Financial raised their target price on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Tuesday, April 7th. BTIG Research reiterated a “buy” rating and issued a $21.00 target price on shares of Theravance Biopharma in a research note on Friday, March 20th. Finally, Weiss Ratings lowered shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 27th. Two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Theravance Biopharma currently has an average rating of “Hold” and a consensus price target of $21.40.

Institutional Trading of Theravance Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP acquired a new stake in Theravance Biopharma in the 3rd quarter worth $26,000. Caitong International Asset Management Co. Ltd grew its position in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its position in Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.